ABCC3

ATP-binding cassette sub-family C member 3 · O15438 · ABCC3 on Sugi Atlas →

58,598 patent compounds predicted against ABCC3, 46,854 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Glimepiride (SCHEMBL16084)	1.00	3/20
Glimepiride (SCHEMBL16086)	1.00	3/20
Rifaximin (SCHEMBL124066)	1.00	3/20
Rifaximin (SCHEMBL124067)	1.00	3/20
Rifaximin (SCHEMBL140435)	1.00	3/20
Rifamycin (SCHEMBL2320)	0.70	3/20
Rifamide (SCHEMBL49236)	0.63	3/20
Rifamide (SCHEMBL49237)	0.63	3/20
Atorvastatin (SCHEMBL3832)	1.00	2/20
Everolimus (SCHEMBL4378)	1.00	2/20
Temsirolimus (SCHEMBL18792)	1.00	2/20
Rifampin (SCHEMBL23490)	1.00	2/20
Rifampin (SCHEMBL23491)	1.00	2/20
Rifampin (SCHEMBL23492)	1.00	2/20
Gliquidone (SCHEMBL37769)	1.00	2/20
Rifapentine (SCHEMBL41590)	1.00	2/20
Rifapentine (SCHEMBL41591)	1.00	2/20
Rifampin (SCHEMBL66289)	1.00	2/20
Atorvastatin (SCHEMBL28456)	0.98	2/20
Atorvastatin (SCHEMBL41065)	0.98	2/20

Clinical trials — most relevant to ABCC3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pharmacogenetics to Predict Drug Interactions in Kidney Transplant Recipients	PHASE4	COMPLETED
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer	PHASE3	COMPLETED
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	PHASE1/PHASE2	COMPLETED
A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI	PHASE1/PHASE2	UNKNOWN
CELECOXIB Plasma and Cerebral Spinal Fluid Pharmacokinetics in Children	PHASE2	RECRUITING
Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas	PHASE2	COMPLETED
Influence of Ethnicity and ABCB1 Gene Polymorphism on the Pharmacokinetics of Azithromycin in Healthy Bangladeshi Volunteers	PHASE1	UNKNOWN
Effect of, OAT3, on the Renal Secretion of Cefotaxime	PHASE1	COMPLETED
Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas	PHASE1	COMPLETED
Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery	PHASE1	COMPLETED
Icotinib Hydrochloride in Treating Patients With Advanced Cancers	PHASE1	WITHDRAWN
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery	PHASE1	COMPLETED
Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia	nan	ACTIVE_NOT_RECRUITING
the Effect of ABCC2 Genetic Polymorphism on Neurotoxicity in Gastrointestinal Cancer Patients Receiving Oxaliplatin	nan	UNKNOWN
Studying DNA in Tissue Samples From Caucasian and African-American Cancer Patients Who Received Docetaxel on Clinical Trial CLB-9871	nan	COMPLETED
Placental Transfer of Tenofovir	nan	COMPLETED
Hydroxychloroquin (HCQ) in chILD of Genetic Defect	nan	COMPLETED
Coproporphyrine Isomers and Methotrexate Elimination	nan	COMPLETED
Genetic Causes and Clinical Features of Childhood Interstitial Lung Diseases in China	nan	COMPLETED
Metformin Reduce the Relapse Rate on Patients With B-cell Precursor (Ph+ Negative) Acute Lymphoblastic Leukemia	nan	COMPLETED
Bile Acids Metabolism and Genetic Mutation Profile in the Intrahepatic Cholestasis of Pregnacy in Indian Population	nan	RECRUITING
Pharmacogenomics of New Antiretrovirals	nan	COMPLETED
Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District	nan	UNKNOWN
Collection of Tissue Samples for Study of Multidrug Resistance	nan	COMPLETED
Role of the ATP7A Transporter in Ovarian Cancer	nan	COMPLETED
Impact of Genetics on Metformin Pharmacokinetics	nan	COMPLETED
Pharmacogenetics Study in Taiwan's Ethnic Groups	nan	COMPLETED
Secondary Sclerosing Cholangitis in Critically Ill Patients	nan	ACTIVE_NOT_RECRUITING
Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients	nan	UNKNOWN
Natural History Study of ATP1A3-related Disease	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a ABCC3 binder may also engage these)

Protein	Name	Similarity
B2RX12	—	0.998	B2RX12 →
O88563	—	0.995	O88563 →
O35379	—	0.989	O35379 →
O88269	—	0.989	O88269 →
Q9R1S7	—	0.988	Q9R1S7 →
Q8HXQ5	—	0.987	Q8HXQ5 →
O95255	—	0.987	O95255 →
ABCC1	Multidrug resistance-associated protein 1	0.987	landscape →
ABCC8	ATP-binding cassette sub-family C member 8	0.987	landscape →
Q864R9	—	0.986	Q864R9 →
Q09429	—	0.986	Q09429 →
Q8CG09	—	0.986	Q8CG09 →
Q5T3U5	—	0.986	Q5T3U5 →
Q6UR05	—	0.984	Q6UR05 →
Q63120	—	0.984	Q63120 →
Q09427	—	0.984	Q09427 →
Q9C8G9	—	0.984	Q9C8G9 →
Q8VI47	—	0.984	Q8VI47 →
TAP1	Antigen peptide transporter 1	0.984	landscape →
Q5F364	—	0.983	Q5F364 →
Q96J66	—	0.982	Q96J66 →
P36370	—	0.981	P36370 →
O70595	—	0.981	O70595 →
Q9QYJ4	—	0.981	Q9QYJ4 →
Q9R1X5	—	0.981	Q9R1X5 →
P21958	—	0.980	P21958 →
A0A0G2K1Q8	—	0.980	A0A0G2K1Q8 →
Q9JJ59	—	0.980	Q9JJ59 →
Q9QYM0	—	0.979	Q9QYM0 →
Q8R420	—	0.979	Q8R420 →